Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1522764

registered interest
date	17/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Voluntary scheme for branded medicines pricing and access, whether her Department has made an assessment of the potential merits of an exemption from payments for new active substances from that scheme.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	64035
answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>The Voluntary Scheme for Branded Medicines Pricing and Access includes a 36 month exemption from payments for drugs containing a new active substance, starting once the marketing authorisation has been granted. Treatment of new active substances under a future voluntary scheme is subject to negotiation.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 16:47:32 answering member 4320 label Biography information for Robert Jenrick
tabling member	3985 label Biography information for Robert Halfon

1521780

registered interest
date	13/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many medicine by presentations included within the Voluntary Patient Access Scheme have had NHS List Price increase approved by their Department since 1 January 2020; and what was the average percentage increase for any such increases.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	62789
answer	answer is ministerial correction date of answer 03/11/2022 answer text <p>Between 1 January 2020 and 14 October 2022, members of the Voluntary Scheme for Branded Medicines Pricing and Access have received approval for an increase to the National Health Service list price for 35 medicines, for 120 presentations. The majority of price increases have been concentrated in specific market segments particularly impacted by global cost increases in the active pharmaceutical ingredient.</p><p>Price increase requests are assessed in line with Scheme’s rules, which ensure companies cannot make excess profits by setting a return on sales target of 6% for standard price increase requests.</p> answering member constituency Colchester answering member printed Will Quince question first answered 03/11/2022 13:28:21 answering member 4423 label Biography information for Will Quince
tabling member	3985 label Biography information for Robert Halfon

1521782

registered interest
date	13/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans her Department has to carry out an impact assessment on the effect of an increased voluntary scheme for branded medicine rate to a projected 23.7 per cent in 2023 upon the supply of medicines to the NHS.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	62790
answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>The Department has no plans to carry out an impact assessment on the 2023 payment percentage. The Department’s standard practice is to set the payment percentage based on measured sales. The payment percentage projected for 2023 is in line with Department projections shared with industry when the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) was agreed.</p><p>We have seen no evidence that increased VPAS payments have or will impact on the supply of medicines to the National Health Service. Where payment rates may put pressure on the profitability of individual products, there are provisions in the scheme for companies to apply for a price increase.</p> answering member constituency Colchester answering member printed Will Quince question first answered 01/11/2022 12:16:12 answering member 4423 label Biography information for Will Quince
tabling member	3985 label Biography information for Robert Halfon

1521787

registered interest
date	13/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to publish data comparing the voluntary scheme for branded medicines pricing and access repayments against leading European countries with similar access or rebate schemes in each year since 2015.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	62791
answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>We have no plans to do so.</p><p>Prices paid for medicines internationally are generally confidential. It is therefore not possible to make an accurate comparison of the net price of medicines between the UK and other countries, with or without rebate rates.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 14:51:43 answering member 4320 label Biography information for Robert Jenrick
tabling member	3985 label Biography information for Robert Halfon

1521788

registered interest
date	13/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason her Department included branded (a) generic and (b) biosimilar medicines that delivered savings to the NHS within the current voluntary scheme for branded medicines pricing and access scheme.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	62792
answer	answer is ministerial correction date of answer 01/11/2022 answer text <p>Medicines which are required to be prescribed by brand name, including some branded generics and biosimilars, are not interchangeable. Therefore, competitive forces will not act in the same way as for generic medicines and price regulation is justified. The inclusion of these medicines in the Voluntary Scheme for Branded Medicines Pricing and Access was agreed with industry in 2019.</p> answering member constituency Colchester answering member printed Will Quince question first answered 01/11/2022 12:23:25 answering member 4423 label Biography information for Will Quince
tabling member	3985 label Biography information for Robert Halfon

1521789

registered interest
date	13/10/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative estimate of the annual savings that (a) unbranded generic, (b) branded generic and (c) biosimilar medicines have contributed to the NHS drug bill compared to branded prices had those medicines not been available for each year since 2012 for which data is available.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	62793
answer	answer is ministerial correction date of answer 25/10/2022 answer text <p>The current Voluntary Scheme for Branded Medicines Pricing and Access expenditure forecast assumes that average spend at patent expiry will decrease by 70% for a non-biologic medicine or 45% for a biologic medicine. The Secretary of State has also commissioned further policy advice on this matter. These assumptions will be reviewed ahead of the negotiation of a new Scheme.</p> answering member constituency Newark answering member printed Robert Jenrick question first answered 25/10/2022 14:44:42 answering member 4320 label Biography information for Robert Jenrick
tabling member	3985 label Biography information for Robert Halfon

1423145

registered interest
date	18/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospices: Apprentices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department (a) has taken and (b) is planning to take to encourage hospices to access Apprenticeship Levy funding.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	125102
answer	answer is ministerial correction date of answer 23/02/2022 answer text <p>We are increasing funding for apprenticeships to £2.7 billion by 2024/25. This will support apprenticeships in non-levy employers, such as hospices, where the Government will continue to pay 95% of training costs.</p><p>Since 1 April 2021, all non-levy paying employers, including hospices, arranging new apprenticeships must do so through the apprenticeship service. This provides more control over apprenticeship choices and the ability to reserve funds before choosing the appropriate apprenticeship provider. All small and medium-sized enterprises, such as hospices, have been able to reserve funding for up to 10 new apprenticeships in 2021/22.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 125103 question first answered 23/02/2022 14:42:37 answering member 4362 label Biography information for Edward Argar
tabling member	3985 label Biography information for Robert Halfon

1423146

registered interest
date	18/02/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospices: Apprentices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the extent of apprenticeship opportunities in the hospice sector.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	125103
answer	answer is ministerial correction date of answer 23/02/2022 answer text <p>We are increasing funding for apprenticeships to £2.7 billion by 2024/25. This will support apprenticeships in non-levy employers, such as hospices, where the Government will continue to pay 95% of training costs.</p><p>Since 1 April 2021, all non-levy paying employers, including hospices, arranging new apprenticeships must do so through the apprenticeship service. This provides more control over apprenticeship choices and the ability to reserve funds before choosing the appropriate apprenticeship provider. All small and medium-sized enterprises, such as hospices, have been able to reserve funding for up to 10 new apprenticeships in 2021/22.</p> answering member constituency Charnwood answering member printed Edward Argar grouped question UIN 125102 question first answered 23/02/2022 14:42:37 answering member 4362 label Biography information for Edward Argar
tabling member	3985 label Biography information for Robert Halfon

1416309

registered interest
date	25/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Israel
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions (a) he and (b) Ministers have had with their Israeli counterparts on tackling covid-19.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	111550
answer	answer is ministerial correction date of answer 31/01/2022 answer text <p>We have had no recent discussions.</p> answering member constituency Chichester answering member printed Gillian Keegan question first answered 31/01/2022 14:05:41 answering member 4680 label Biography information for Gillian Keegan
tabling member	3985 label Biography information for Robert Halfon

1388754

registered interest
date	16/12/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Disease Control
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with his Israeli counterpart on tackling the omicron variant of covid-19.
tabling member constituency	Harlow
tabling member printed	Robert Halfon
uin	94336
answer	answer is ministerial correction date of answer 05/01/2022 answer text <p>There have been no recent discussions on Omicron between the Health Secretary Sajid Javid and the Israeli Health Minister Nitzan Horowitz.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 05/01/2022 13:44:43 answering member 4362 label Biography information for Edward Argar
tabling member	3985 label Biography information for Robert Halfon